LLY

Eli Lilly & Co
D

LLY

Arincen80/100B

Eli Lilly & Co income statement 1985–2026

86.46B USD over the last twelve months, and 65.18B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
86.46B65.18B45.04B34.12B28.54B28.32B24.54B22.32B21.49B19.97B21.22B
Revenue growth
+45.51%+44.70%+32.00%+19.56%+0.79%+15.40%+9.95%+3.84%+7.61%-5.88%+6.33%
Cost of revenue
14.15B11.05B8.42B7.08B6.63B7.31B5.48B4.72B4.68B4.45B5.71B
Gross profit
72.31B54.13B36.63B27.04B21.91B21.01B19.06B17.60B16.81B15.53B15.51B
Gross margin
83.63%83.04%81.31%79.25%76.77%74.18%77.66%78.85%78.22%77.73%73.09%
Research and development
15.38B13.34B10.99B9.31B7.19B6.93B5.98B5.60B5.05B5.10B5.31B
Selling, general and administrative
12.62B11.09B8.59B6.94B6.07B6.14B5.87B6.00B5.73B6.18B6.33B
Operating expenses
32.48B24.43B19.59B16.25B13.26B13.07B11.85B11.60B10.79B11.28B11.64B
39.83B29.70B17.04B10.79B8.65B7.93B7.21B6.00B6.03B4.25B3.87B
Operating income growth
+50.92%+74.27%+57.96%+24.66%+9.08%+10.02%+20.19%-0.44%+41.79%+9.78%+7.77%
Operating margin
46.07%45.56%37.83%31.61%30.32%28.01%29.38%26.88%28.04%21.28%18.24%
Interest income
—153.30M175.20M173.60M62.80M25.40M33.00M80.40M159.30M166.40M108.70M
Interest expense
1.18B795.30M780.60M485.90M331.60M339.80M359.60M400.60M242.50M225.00M185.20M
Other non-operating income
-5.06B-3.97B-4.36B-4.23B-1.85B-1.78B19.10M-733.50M-2.35B-1.95B-497.30M
Pretax income
34.77B25.73B12.68B6.55B6.81B6.16B7.23B5.27B3.68B2.30B3.37B
Income tax
7.19B5.09B2.09B1.31B561.60M573.80M1.04B628.00M529.50M2.39B636.40M
Effective tax rate
20.68%19.79%16.48%20.05%8.25%9.32%14.33%11.93%14.39%103.75%18.86%
27.58B20.64B10.59B5.24B6.24B5.58B6.19B8.32B3.23B-204.10M2.74B
Net income growth
+49.79%+94.90%+102.08%-16.08%+11.88%-9.88%-25.54%+157.38%—-107.46%+13.67%
Net margin
31.90%31.67%23.51%15.36%21.88%19.71%25.24%37.27%15.04%-1.02%12.90%
Basic shares
894.20M898.00M900.61M899.38M950.18M953.65M956.59M957.53M1.03B1.05B1.10B
Diluted shares
895.25M898.00M904.06M903.28M904.62M911.68M956.59M957.53M1.03B1.05B1.10B
Change in diluted shares
-0.59%-0.67%+0.09%-0.15%-0.77%-4.69%-0.10%-7.37%-1.74%-4.44%-0.40%
EPS (basic)
30.8923.0711.765.836.575.856.478.693.14-0.192.49
EPS (diluted)
30.8122.9511.715.806.906.126.478.693.13-0.192.49
EPS growth
+50.73%+95.99%+101.90%-15.94%+12.75%-5.41%-25.55%+177.64%—-107.63%+14.22%
Dividends per share
6.696.005.204.523.923.402.962.582.252.082.04
Dividend growth
+15.34%+15.38%+15.04%+15.31%+15.29%+14.86%+14.73%+14.67%+8.17%+1.96%+2.00%
EBITDA
44.75B31.69B18.81B8.57B8.66B8.04B8.91B6.90B5.53B4.10B5.06B
EBITDA margin
51.76%48.62%41.75%25.11%30.34%28.40%36.32%30.91%25.74%20.51%23.82%
EBIT
42.58B29.70B17.04B7.04B7.14B6.50B7.59B5.67B3.92B2.53B3.56B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Eli Lilly & Co's income statement

Source: Financial Modeling Prep